Literature DB >> 2439796

Affinity and selectivity of beta-adrenoceptor antagonists in vitro.

A Wellstein, D Palm, G G Belz.   

Abstract

The potency order of the catecholamines (-)-isoprenaline (Iso), (-)-noradrenaline (NA), and (-)-adrenaline (Adr) in competition for radiolabelled sites is used for their pharmacological classification. It is shown that the radioligand 3H-CGP 12177 exclusively labels beta 1-adrenoceptors in rat salivary gland membranes (Iso greater than NA greater than Adr), and beta 2-adrenoceptors in rat reticulocytes (Iso greater than Adr greater than or equal to NA). These models are then used to derive the subtype-selectivity of the classical beta-adrenoceptor antagonists (+/-)-propranolol (prop; twofold beta 2-selective) and (+/-)-atenolol (aten; 35-fold beta 1-selective), as well as of the newer antagonists (+/-)-betaxolol and (+/-)-bisoprolol (betax and biso; 35-fold and 75-fold beta 1-selective, respectively). The ligand with the highest selectivity is ICI 118,551 (ICI), with a 300-fold beta 2-subtype selectivity. For comparison with antagonistic effects in humans at given plasma concentrations, the equilibrium dissociation constants of the ligands are measured in the presence of native human plasma and yield values for the relative selectively labelled subtype in the mean (Ki-values in nmol/l): prop: 20, aten: 250, biso: 24, betax: 23, and ICI: 2.5.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2439796     DOI: 10.1097/00005344-198511001-00006

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  11 in total

1.  β-adrenergic receptor mediation of stress-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: roles for β1 and β2 adrenergic receptors.

Authors:  Oliver Vranjkovic; Shona Hang; David A Baker; John R Mantsch
Journal:  J Pharmacol Exp Ther       Date:  2012-05-16       Impact factor: 4.030

2.  A randomized double-blind study of bisoprolol versus atenolol in mild to moderate essential hypertension.

Authors:  M S Dixon; P Thomas; D J Sheridan
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

4.  Effect of bisoprolol on cardiac performance in coronary heart disease.

Authors:  B Maisch; U Borst; W Gerhards; G Wagner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Role of beta2-adrenoceptors (beta-AR), but not beta1-, beta3-AR and endothelial nitric oxide, in beta-AR-mediated relaxation of rat intrapulmonary artery.

Authors:  Fabrice Pourageaud; Véronique Leblais; Nadège Bellance; Roger Marthan; Bernard Muller
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-08-26       Impact factor: 3.000

6.  The affinity of betaxolol, a beta 1-adrenoceptor-selective blocking agent, for beta-adrenoceptors in the bovine trachea and heart.

Authors:  E Satoh; A Narimatsu; Y Hosohata; H Tsuchihashi; T Nagatomo
Journal:  Br J Pharmacol       Date:  1993-02       Impact factor: 8.739

Review 7.  Nonresponsiveness to antianginal therapy--a frequent problem?

Authors:  W Schulz
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

8.  Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties.

Authors:  C Volz-Zang; B Eckrich; P Jahn; B Schneidrowski; B Schulte; D Palm
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  In-vitro relationship between protein-binding and free drug concentrations of a water-soluble selective beta-adrenoreceptor antagonist (atenolol) and its interaction with arsenic.

Authors:  M A Alam; M A Awal; N Subhan; M Mostofa
Journal:  J Health Popul Nutr       Date:  2009-02       Impact factor: 2.000

10.  Efficacy and tolerability of a β-1 selective β blocker, bisoprolol, as a first-line antihypertensive in Indian patients diagnosed with essential hypertension (BRIGHT): an open-label, multicentric observational study.

Authors:  V Channaraya; R K Marya; M Somasundaram; Debashish Mitra; K D Tibrewala
Journal:  BMJ Open       Date:  2012-05-14       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.